For research laboratories focused on immunology, oncology, or autoimmune disease mechanisms, sourcing high-quality reagents is paramount. Daclizumab, a humanized monoclonal antibody targeting the CD25 antigen, is one such compound that, despite its clinical withdrawal, retains significant research utility. This guide is designed for procurement managers and research scientists who need to buy Daclizumab, offering insights into its applications and the procurement process.

Daclizumab functions by binding to the CD25 component of the IL-2 receptor, thereby inhibiting T-cell activation. This mechanism was leveraged for two main clinical purposes: preventing acute rejection in organ transplantation and treating relapsing forms of multiple sclerosis (MS). Although these therapeutic uses have been discontinued due to serious safety issues, including inflammatory brain disorders and liver toxicity, the antibody's targeted action makes it an invaluable tool for scientific investigation. Researchers frequently purchase Daclizumab to explore these very pathways.

When embarking on the procurement of Daclizumab, several key considerations come into play. Firstly, the source of the product is critical. Identifying reliable manufacturers and suppliers is essential to ensure product purity, consistent quality, and proper handling. Laboratories often look to specialized chemical suppliers, including those based in China known for their competitive pricing and extensive catalogs of biochemicals, to source Daclizumab. The availability of detailed Certificates of Analysis (CoA) is a standard requirement to verify the product's specifications.

Secondly, understanding the research context for Daclizumab is important. While it is no longer used clinically, its role in understanding T-cell mediated immunity, cytokine signaling, and the pathogenesis of autoimmune diseases remains relevant. Researchers might buy Daclizumab to study its effects on immune cell populations, to develop new assays, or as a reference standard in comparative studies. The historical safety data also provides valuable context for ongoing research into safer immunomodulatory therapies.

Procurement managers should prioritize suppliers who offer robust technical support and timely delivery, especially for temperature-sensitive biologics like Daclizumab. Establishing relationships with trusted chemical companies can streamline the acquisition process and ensure a steady supply for ongoing research projects. Inquiring about shipping conditions, storage recommendations, and return policies is also part of due diligence when purchasing specialized research reagents.

In conclusion, Daclizumab, despite its market withdrawal, continues to be a valuable asset for scientific research. Its specific target and mechanism of action provide unique opportunities for investigating immune system regulation. By carefully selecting suppliers and understanding the compound's research applications and safety profile, laboratories can effectively source Daclizumab to drive their groundbreaking studies forward.